Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$164.99 USD

164.99
4,600,299

-2.37 (-1.42%)

Updated Sep 5, 2024 04:00 PM ET

After-Market: $164.96 -0.03 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

3 Top Dividend Stocks to Maximize Your Retirement Income

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Johnson & Johnson (JNJ) Stock Falls Amid Market Uptick: What Investors Need to Know

In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $146.97, denoting a -1.82% change from the preceding trading day.

Lilly (LLY) Hits Record High on Crohn's Disease Study Data

Eli Lilly's (LLY) stock hits an all-time high after announcing detailed results from a late-stage study on mirikizumab in Crohn's disease.

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

J&J (JNJ) to Boost Dermatology Portfolio With New Acquisition

Johnson & Johnson (JNJ) inks deal to acquire Proteologix, Inc. for $850 million in cash. The transaction is expected to be closed in mid-2024.

Kinjel Shah headshot

Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates

Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.

Johnson & Johnson (JNJ) Up 5.5% Since Last Earnings Report: Can It Continue?

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Bayer (BAYRY) Q1 Earnings Fall Y/Y on Lower Product Sales

Bayer's (BAYRY) Q1 earnings and sales decline year over year due to a fall in volumes for non-glyphosate-based herbicides and lower prices for glyphosate-based products in the Crop Science division.

Johnson & Johnson (JNJ) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up

TEVA reports mixed first-quarter results, missing estimates for earnings but beating the same for sales. It announces promising data from a phase III study on schizophrenia candidate, olanzapine.

3 Top Dividend Stocks to Maximize Your Retirement Income

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates

Halozyme (HALO) reports mixed first-quarter 2024 earnings. The company maintains revenue guidance for 2024.

The Zacks Analyst Blog Highlights Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips

Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips are included in this Analyst Blog.

Sheraz Mian headshot

Q1 Earnings Season Scorecard and Fresh Analyst Reports for Tesla, JNJ & Netflix

Today's Research Daily features the Q1 earnings season scorecard and updated analyst reports on Tesla (TSLA), JNJ (JNJ), Netflix (NFLX) and others.

Sweta Killa headshot

A Look at Pharma ETFs Post Q1 Earnings

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

Kinjel Shah headshot

Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims

Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE) and AbbVie (ABBV) announce their first-quarter results.

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance

GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales for the full year.

AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View

AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.